


ATLANTA, GEORGIA, USA, 13-17 NOVEMBER 2016



MMV & PARTNERS @ ASTMH 2016

65th Annual Meeting
Atlanta Marriott Marquis

- **Symposia**
- **Scientific session**
- **Poster sessions**

Defeating Malaria Together

MMV 
Medicines for Malaria Venture

Symposia



Symposium 64

Atlanta
Marriott Marquis
Room A703/A704
Tuesday 15 Nov
8.00 am to 9.45 am

Where will the next malaria medicines come from?

Chair: **James Duffy**
Medicines for Malaria Venture, Switzerland

Co-Chair: **Elizabeth Winzeler**
Professor of Pediatrics, Division of Pharmacology and Drug Discovery, UCSD

Speakers and topics:

- **The pipeline for new malaria medicines: the good and the bad news**
James Duffy
- **What can be learnt from the phenotypic screening of over 6 million compounds?**
Javier Gamo, GSK, Spain
- **Screening new compounds: what and why?**
Beatriz Baragana, University of Dundee, Scotland
- **Target-based screening for malaria**
Al Edwards, Structural Genomics Consortium, Canada

Scientific
session



Scientific session

Atlanta
Marriott Marquis
Room D
Monday 14 Nov
9.00 am to 9.15 am

6: Malaria: Drug Development – Preclinical to Clinical Trials

26

Assessing the speed of clearance of *Plasmodium vivax* from the blood following treatment with a licensed and experimental antimalarials

Presenter

James S. McCarthy, QIMR Berghofer Medical Research Institute, Australia



Poster
sessions



Poster sessions

Hilton
Grand Ballroom
and Grand Salon
Tuesday 15 Nov
12.00 pm to 1.45 pm

Poster Session B: Presentations and Light Lunch

- 858** Defining the desired attributes of a next-generation SMC drug
Presenter **André-Marie Tchouatieu**, Medicines for Malaria Venture, Switzerland
-
- 1012** Evaluating the potential to transmit malaria from humans to mosquitoes during controlled human malaria infection with *P. falciparum* and *P. vivax*
Presenter **Katharine A. Collin**, QIMR Berghofer Medical Research Institute, Australia



Poster sessions

Hilton
 Grand Ballroom
 and Grand Salon
 Wednesday 16 Nov
 12.00 pm to 1.45 pm

Poster Session C: Presentations and Light Lunch

- | | |
|------|---|
| 1534 | <p>A proof-of-concept, randomized study in non-immune healthy adult volunteers to investigate the safety, tolerability, pharmacokinetic profile and prophylactic activity of a single dose of DSM265 in a controlled human malarial infection challenge either by direct venous inoculation of <i>P. falciparum</i> sporozoites (PfSPZ) or a single episode of bites by mosquitoes carrying <i>P. falciparum</i></p> <p>Presenter Sean C. Murphy, University of Washington Medical Center, USA</p> |
| 1535 | <p>Phase IIb study of artefenomel (OZ439) and piperazine to investigate single dose treatment for uncomplicated <i>P. falciparum</i> malaria</p> <p>Presenter Fiona Macintyre, Medicines for Malaria Venture, Switzerland</p> |
| 1540 | <p>Moderate and severe LFT elevations in controlled human <i>P. falciparum</i> malaria infection model: recent experience, literature review and mechanistic hypotheses</p> <p>Presenter Stephan Chalon, Medicines for Malaria Venture, Switzerland</p> |
| 5390 | <p>Can improved case management affect malaria transmission? Initial outcomes from a study in Odisha, India</p> <p>Presenter Dr Anup Anvika, National Institute of Malaria Research, India</p> |

Medicines for Malaria Venture's vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease. www.mmv.org | info@mmv.org

Photos: Jaya Banerji/MMV (cover), Anna Wang/MMV (p.2), Eskitis Institute (p.3), Griffith University (p.4), MMV (p.5), Feliciano Monti (p.6), Jenn Warren (p.7)

MMV-SUPPORTED PROJECTS

Antimalarial drug discovery and development projects scientifically and/or financially supported by MMV (3rd Quarter, 2016).

